EcoDrugPlus

Microtubule-Associated Protein Tau

Ensembl ID : ENSOKIG00005015162
Gene Symbol: LOC109865548
2 Cross references
206 Possible Orthologues:

Microtubule-Associated Protein Tau

Ensembl ID : ENSOKIG00005011972
Gene Symbol: LOC109893211
2 Cross references
180 Possible Orthologues:

Mineralocorticoid Receptor

Ensembl ID : ENSOKIG00005025703
Gene Symbol: LOC109901290
3 Cross references
207 Possible Orthologues:

Mineralocorticoid Receptor-Like

Ensembl ID : ENSOKIG00005003769
Gene Symbol: LOC109881008
3 Cross references
203 Possible Orthologues:

Mitogen-Activated Protein Kinase 1

Ensembl ID : ENSOKIG00005024341
Gene Symbol: LOC109898211
3 Cross references
191 Possible Orthologues:

Mitogen-Activated Protein Kinase 1

Ensembl ID : ENSOKIG00005004216
Gene Symbol: LOC109881705
3 Cross references
159 Possible Orthologues:

Mitogen-Activated Protein Kinase 1-Like

Ensembl ID : ENSOKIG00005032714
Gene Symbol: LOC109893105
3 Cross references
192 Possible Orthologues:

Mitogen-Activated Protein Kinase 1-Like

Ensembl ID : ENSOKIG00005012354
Gene Symbol: LOC109882760
2 Cross references
192 Possible Orthologues:

Mitogen-Activated Protein Kinase 10

Ensembl ID : ENSOKIG00005007381
Gene Symbol: LOC109877945
3 Cross references
82 Possible Orthologues:

Mitogen-Activated Protein Kinase 10-Like

Ensembl ID : ENSOKIG00005028404
Gene Symbol: LOC109892306
3 Cross references
81 Possible Orthologues:

Mitogen-Activated Protein Kinase 11

Ensembl ID : ENSOKIG00005032579
Gene Symbol: MAPK11
3 Cross references
152 Possible Orthologues:

Mitogen-Activated Protein Kinase 11-Like

Ensembl ID : ENSOKIG00005007146
Gene Symbol: LOC109910317
3 Cross references
188 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).